Ascendis Pharma ASMEX:ASNDN 37 Return-on-Tangible-Equity is 1,593.97% as of Mar. 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,206 Biotechnology companies, Ascendis Pharma AS ranks better than 99.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ascendis Pharma AS's annualized net income for the quarter that ended in Mar. 2026 was MXN52,479 Mil. Ascendis Pharma AS's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN3,292 Mil. Therefore, Ascendis Pharma AS's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 1,593.97%.
The historical rank and industry rank for Ascendis Pharma AS's Return-on-Tangible-Equity or its related term are showing as below:
MEX:ASNDN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -953.26 Med: -58.29 Max: -43.22
Current: Negative Tangible Equity
During the past 13 years, Ascendis Pharma AS's highest Return-on-Tangible-Equity was -43.22%. The lowest was -953.26%. And the median was -58.29%.
MEX:ASNDN's Return-on-Tangible-Equity is ranked better than 99.92% of 1206
companies
in the Biotechnology industry
Industry Median: -42.53
vs MEX:ASNDN: Negative Tangible Equity
Ascendis Pharma AS (MEX:ASNDN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ascendis Pharma AS Return-on-Tangible-Equity Related Terms
Ascendis Pharma AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS Return-on-Tangible-Equity Chart
MEX:ASNDN vs SMMT, BBIO, JAZZ: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1,593.97% mean?
Ascendis Pharma AS (MEX:ASNDN) has a Return-on-Tangible-Equity of 1,593.97% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #1 out of 1206 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Ascendis Pharma AS's Return-on-Tangible-Equity too high?
Ascendis Pharma AS's current Return-on-Tangible-Equity is 1,593.97%. Based on the distribution chart, Ascendis Pharma AS ranks #1 out of 1206 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Return-on-Tangible-Equity compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #1 out of 1206 companies for Return-on-Tangible-Equity. This places Ascendis Pharma AS in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Return-on-Tangible-Equity is 1,593.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current Return-on-Tangible-Equity of 1,593.97%. The current Return-on-Tangible-Equity is 1,593.97%. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current Return-on-Tangible-Equity is 1,593.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
